We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

Clinical Study Of Proprietary Probiotic Shows Significant Cholesterol Reduction

November 6, 2012: 12:00 AM EST
A clinical study funded by an eight-year-old Canadian company reports that taking the company’s proprietary probiotic twice a day lowers key cholesterol-bearing molecules in the blood and reduces levels of both “bad” and total cholesterol. For the study, about half of the 127 adult patients with high cholesterol took L. reuteri NCIMB 30242 twice a day, half took placebo capsules. Those taking the probiotic had LDL levels 11.6 percent lower than those on placebo after nine weeks. Cholesterol esters dropped by 6.3 percent and cholesterol ester saturated fatty acids by 8.8 percent among the probiotic group. Micropharma, which funded the study, is expected to introduce the product (Cardioviva) in the U.S. in 2013.
Mitchell L. Jones, M.D., Ph.D. et al., "Daily Doses of a New Probiotic Reduces Bad and Total Cholesterol", News release, presentation at the American Heart Association's Scientific Sessions 2012, November 06, 2012, © Jones et al.
Food & Nutrition
Heart & Cardiovascular
Pills & Supplements
North America
Companies, Organizations
Market News
Products & Brands
Research, Studies, Advice
Developed by Yuri Ingultsov Software Lab.